Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, announced today the first patient, first visit for PIVOT-PO, a global pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). Spero is entitled to receive $95 million in development milestone payments from GSK, which is payable in four equal installments over two years.
Related news for (SPRO)
- Today’s Top Performers: MoBot’s Market Review 05/30/25 09:00 AM
- Biotech Today: From Sustainable Biomaterials to First-in-Class Therapies
- Today’s Top Performers: MoBot’s Market Review 05/28/25 07:00 AM
- Spero Therapeutics and GSK Announce Early Completion of Phase 3 PIVOT-PO Trial for Oral Antibiotic Tebipenem HBr Based on Positive Efficacy Results
- Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee